Janssen Pharmaceuticals, Inc. has completed the divestiture of its U.S. license rights to Nucynta (tapentadol), Nucynta ER extended-release tablets and Nucynta oral solution to Depomed for $1.05 billion. Janssen’s licensed U.S. commercialization rights to Nucynta products from Grunenthal GmbH were assigned to Depomed. Janssen will retain license rights to the products in Canada, Japan, and a number of other countries outside the U.S....